4th Quarter - Amendment
VENN STRATEGIES for AVANIR PHARMACEUTICALS, INC.
Firm
Client
Income
$40,000
Expenses
—
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 20, 2022 | $40,000 | Replaced |
| 4th Quarter - Amendment (this page) | Feb 4, 2022 | $40,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
Foreign entity interest: Ownership
| Lobbyist | Covered position, as disclosed |
|---|---|
| GRANT COUCH | — |
| STEPHANIE SILVERMAN | — |
| MICHAEL SPIRA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.